⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 16, 2024

Supplementary Data from Syk inhibition reprograms tumor-associated macrophages and overcomes gemcitabine-induced immunosuppression in pancreatic ductal adenocarcinoma

Deepak Rohila In Hwan Park Timothy V. Pham Jonathan Weitz Tatiana Hurtado de Mendoza Suresh Madheswaran Mehreen Ishfaq Cooper Beaman Elisabette Tapia Siming Sun Jay Patel Pablo Tamayo Andrew M. Lowy Shweta Joshi

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Supplementary methods and Legends to supplementary figures

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rohila et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db643587523122 https://doi.org/10.1158/0008-5472.27028201

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Data from Syk inhibition reprograms tumor-associated macrophages and overcomes gemcitabine-induced immunosuppression in pancreatic ductal adenocarcinoma2024
2Data from Syk inhibition reprograms tumor-associated macrophages and overcomes gemcitabine-induced immunosuppression in pancreatic ductal adenocarcinoma2024
3Supplementary Data 1 from MEK inhibition sensitizes pancreatic cancer to STING agonism by tumor-cell intrinsic amplification of type I interferon signaling2024
4Supplementary Data 1 from MEK inhibition sensitizes pancreatic cancer to STING agonism by tumor-cell intrinsic amplification of type I interferon signaling2024
5Supplementary Figure S8 from PAD2-Mediated Histone Citrullination Drives Tumor Progression by Enhancing Cell Proliferation and Modifying the Microenvironment in Pancreatic Cancer2025